Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc. operates in various business sectors.
Aldeyra Therapeutics Inc. (137) - Total Assets
Latest total assets as of June 2024: €126.04 Million EUR
Based on the latest financial reports, Aldeyra Therapeutics Inc. (137) holds total assets worth €126.04 Million EUR as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aldeyra Therapeutics Inc. - Total Assets Trend (2018–2023)
This chart illustrates how Aldeyra Therapeutics Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Aldeyra Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2023)
Aldeyra Therapeutics Inc.'s total assets of €126.04 Million consist of 99.7% current assets and 0.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 96.3% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how Aldeyra Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aldeyra Therapeutics Inc.'s current assets represent 99.7% of total assets in 2023, a decrease from 99.7% in 2018.
- Cash Position: Cash and equivalents constituted 96.3% of total assets in 2023, up from 49.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Aldeyra Therapeutics Inc. Competitors by Total Assets
Key competitors of Aldeyra Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
| No similar companies found. | ||
Aldeyra Therapeutics Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Aldeyra Therapeutics Inc. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Aldeyra Therapeutics Inc. is currently not profitable relative to its asset base.
Aldeyra Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.55 | 9.96 | 20.66 |
| Quick Ratio | 4.55 | 9.96 | 20.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €98.05 Million | € 139.87 Million | € 234.83 Million |
Aldeyra Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Aldeyra Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -18.2% |
| Total Assets | €148.33 Million |
| Market Capitalization | $44.97K USD |
Valuation Analysis
Below Book Valuation: The market values Aldeyra Therapeutics Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Aldeyra Therapeutics Inc.'s assets decreased by 18.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Aldeyra Therapeutics Inc. (2018–2023)
The table below shows the annual total assets of Aldeyra Therapeutics Inc. from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | €148.33 Million | -18.18% |
| 2022-12-31 | €181.29 Million | -22.24% |
| 2021-12-31 | €233.14 Million | +179.70% |
| 2020-12-31 | €83.35 Million | +10.37% |
| 2019-12-31 | €75.52 Million | -20.58% |
| 2018-12-31 | €95.09 Million | -- |